NCT07065617

A Study to Test How BI 1819479 is Taken up and Processed by the Body

A Phase I, Open-label, Two-part Trial to Investigate the Mass Balance, Metabolism, and Basic Pharmacokinetics of BI 1819479 (C-14) Administered as an Oral Solution (Part A) and to Investigate the Absolute Bioavailability of BI 1819479 Administered as a Film-coated Tablet Together With an Intravenous Microtracer Dose of [14 C]BI 1819479 (Part B) in Healthy Male Volunteers

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This trial is intended to investigate the mass balance, metabolism, and basic pharmacokinetics of BI 1819479 (C-14) (Part A) and to investigate the absolute bioavailability of BI 1819479 (Part B) in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[14C]BI 1819479	\[14C\]BI 1819479
DRUG	BI 1819479	BI 1819479
DRUG	BI 1819479 (C-14)	BI 1819479 mixed with \[14C\]BI 1819479

Timeline

• Start date: 2025-08-04
• Primary completion: 2025-10-04
• Completion: 2025-11-04
• First posted: 2025-07-15
• Last updated: 2026-03-17

Locations

1 site across 1 country: United Kingdom